All News Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
27.69 ^USD	-0.89%		+14.00%	+166.25%

May. 16	HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target	MT
May. 10	Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

HC Wainwright Initiates Dianthus Therapeutics With Buy Rating, $40 Price Target	May. 16	MT
Wedbush Adjusts Dianthus Therapeutics' Price Target to $38 From $33, Keeps Outperform Rating	May. 10	MT
Dianthus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results	May. 09	AQ
Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference	May. 08	AQ
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	May. 03	AQ
Lei Meng Announces Not to Stand for Reelection as Director of Dianthus Therapeutics, Inc	Apr. 11	CI
Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting	Apr. 11	AQ
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 05	AQ
Wedbush Raises Dianthus Therapeutics' PT to $33 From $24, Says Q4 2023 Results As-Expected, Keeps Outperform Rating	Mar. 22	MT
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results	Mar. 21	AQ
Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	Mar. 07	AQ
Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)	Feb. 26	AQ
Dianthus Therapeutics, Inc. Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis	Feb. 26	CI
Stifel Initiates Dianthus Therapeutics With Buy Rating, $44 Price Target	Feb. 15	MT
Wedbush Lifts Dianthus Therapeutics' PT to $24 From $23, Updates Estimates Following Private Placement; Keeps Outperform Rating	Jan. 26	MT
Dianthus Therapeutics, Inc. announced that it expects to receive $229.997318 million in funding	Jan. 21	CI
Jefferies Initiates Dianthus Therapeutics at Buy With $22 Price Target	Dec. 26	MT
Dianthus Therapeutics, Inc. Announces Executive Appointments	Nov. 29	CI
Wedbush Starts Dianthus Therapeutics With Outperform Rating, $23 Price Target; Sees DNTH103 as Promising Candidate	Nov. 22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Dianthus Therapeutics, Inc.

Equities

DNTH

US2528281080

All News

Filters